Novo Nordisk’s Clinical Win and Competitive Crossroads
Novo Nordisk’s etavopivat meets Phase 3 goals in sickle cell disease, a bright spot as shares fall 23%…
Novo Nordisk’s Clinical Win and Competitive Crossroads
Novo Nordisk’s etavopivat meets Phase 3 goals in sickle cell disease, a bright spot as shares fall 23%…
Novo Nordisk’s Strategic Pivot Faces Crucial First-Quarter Test
Novo Nordisk shares down 20% YTD as it faces new oral obesity drug competition from Eli Lilly and…
Novo Nordisk’s Share Buyback Defies a Challenging Outlook
Novo Nordisk spends billions on share buybacks despite forecasting a 5-13% sales and profit decline for 2026. Stock…